GLPG: Galapagos Genomics Company Value to Net Income

Corporate emblem and logo of Galapagos N.V. (GLPG)

Despite geopolitical instability in Europe, Galapagos NV (GLPG) is protected by colossal expenditures on its scientific foundation and certification. The company's monthly P/E dynamics on GURU.Markets help balance these risks, where 4.70 reflects the latest metric value. Business stability is confirmed by planned laboratory capacity utilization and strict compliance of equipment with international manufacturing standards.

GLPG Galapagos Corp: Price to Earnings Ratio in the range 03/06/2023 - 05/08/2026

Comprehensive metric breakdowns and analytics for Galapagos N.V. (GLPG)

- price and consensus price forecast:
Stock Price Galapagos Genomics|GLPG - Consensus Target
- market capitalization information:
Market Value Galapagos Genomics|GLPG - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Galapagos|GLPG - Company Net Assets|Market Cap to Book Value Multiple glpg.com|GLPG - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Galapagos NV|GLPG - Long-Term Debt to Capital|Current Liabilities to Capital glpg.com|GLPG - Company Debts|Debt to Net Assets Ratio Galapagos N.V.|GLPG - Company Long-Term Debts|Short-Term Indebtedness Galapagos|Quick Ratio glpg.com
- business earnings and investment ratios data:
GLPG - Company Net Income|Expected Profit Galapagos NV|GLPG - P/E Multiple|Forward P/E Multiple Galapagos Corp|GLPG - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Galapagos N.V.|GLPG - Operating profit EBITDA|Net earnings per share (EPS TTM) Galapagos|GLPG - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year glpg.com|GLPG - Earnings per share growth in current year|Expected net earnings per share growth next year Galapagos NV
- issuer revenue and sales details:
GLPG - Company Revenue|Company Future Sales Galapagos Genomics|GLPG - Market Cap to Revenue|Forward Price to Sales Galapagos Genomics
Comprehensive company analysis:Galapagos - GLPG
Flagship merchandise of Galapagos

The P/E ratio determines the market value of a single unit of profit, reflecting investor expectations regarding future growth rates and the fundamental value of the business. When analyzing the calculated P/E of Galapagos NV (GLPG) on the GURU.Markets platform, it should be noted that the strategic alliance of Galapagos NV in the field of immunology reduces operational risks, transforming the multiplier's volatility into an indicator of market confidence in the success of joint biotechnological developments.

Key competitors

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|ANIP (ANI Pharmaceuticals Inc) - P/E Multiple|Market Cap to Earnings mannkindcorp.com MNKD|Price to Earnings Ratio Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals Inc)|Market Price to Net Income Ratio TBPH (Theravance)|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)